View Mobile Friendly Conference List »

Setting new standards in information exchange for the pharmaceutical and biotech industry


Conference Forum Presented Immuno-Oncology Panel Discussion During the JP Morgan HealthCare Conference

  • January 17, 2017

  • The Conference Forum was delighted to work with a group of leaders in the field of immuno-oncology on a panel focused on Filtering the Hype for the Next Wave of Targets during the JP Morgan Healthcare conference.

    Axel Hoos, MD, PhD, SVP Oncology R&D, GSK and Co-ChairIO360

    Ira Mellman, PhD
    , VP, Cancer Immunology, Genentech

    Lindee Goh
    , Partner, Tapestry Networks

    Omid Hamid, MD
    , Chief, Translational Research and Immunotherapy / Director, Melanoma Therapeutics, The Angeles Clinic

    Ramy Ibrahim, MD
    , VP and Head of R&D, Parker Institute for Cancer Immunotherapy

    IOJPMpanelKey topics addressed included next-generation I/O therapeutics, check point inhibitors, biomarker strategies, coordinating across industry for better approaches to demonstrate value, the future of combinations, the need for high value investigations, challenges with disease modifying medicines, different pathways of costs and coverage for personalized medicine and more. The panel was moderated by Querida Anderson, Editor-in-Chief, BioPharm Insight. After the panel, BioPharm Insight hosted a packed-out reception which took place early evening on January 9th  at the Chandran Art Gallery in San Francisco. If you missed the panel, the Conference Forum is presenting the IO360 conference with over 50 leaders in immuno-oncology on February 1-3 in NYC. For more information, click here.

    Huge thanks to all the panelists, Kate Woda for organizing the panel and our friends at BioPharm Insights for a great job on the overall event.